Show results for
Refine by
Applications
- Microbiome Therapeutics for Patients and Physicians
- Vaccine for COVID-19
- BSD-2000 - Deep Regional Hyperthermia System for Clinical
- Medical cannabis solutions for regulatory pathway sector
- Medical cannabis solutions for mental health costs sector
- IONICON PTR-TOF instruments deployed for COVID-19 detection in breath
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiota for Restoration Therapy
- Microbiota Based Product for Physician-Sponsored Studies
- Solution for Clinical Trials
- Solution for Access to Investigational Medicines
- Liquid Biopsy Technology for Hereditary Cancer Screening
Clinical Phase Equipment & Supplies In Nepal
133 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:RapiGEN Inc. based inSuwon-si, SOUTH KOREA
NS1 (non-structural protein 1) is a highly conserved glycoprotein that is essential for the viability of the Dengue virus and is produced both in membrane-associated and secretory forms by the virus. NS1 antigen is present at a high concentration in the blood of dengue virus-infected patients during the early clinical phase of the ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
Its intelligent Vision AI and machine learning platform aids scientists in refining the prediction of new drug candidates, enhancing translation from preclinical to clinical phases while minimizing failure ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
With V-306 Virometix offers a differentiated approach to RSV vaccine development. Our vaccine candidate – already in clinical phase I – demonstrates strong, durable, specific and protective immune responses, with minimal risk of vaccine-associated enhanced respiratory disease ...
Manufactured by:MitoImmune Therapeutics Inc. based inGangnam-gu, SOUTH KOREA
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological cancer with a high incidence and severity of oral mucositis as a side effect of chemoradiation ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:SiO2 Materials Science based inAuburn, ALASKA (USA)
We provide a common drug contact surface starting at the research and pre-clinical drug development phases, through clinical trials, and on through to commercial ...
Manufactured by:CanaQuest Medical Corp. based inMississauga, ONTARIO (CANADA)
Clinical testing on humans can only begin after a pre-clinical phase, involving laboratory studies (in vitro) and tests on animals, which has shown that the experimental drug is considered safe and effective. However, no animal is sufficiently similar to humans (even genetically modified ones) to make human testing unnecessary. ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in women with high fracture ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United States. It demonstrated favorable safety and tolerability profile in a prospective, open-label, dose-escalation Phase 1 ...
Manufactured by:Triple Hair Inc. based inDieppe, NEW BRUNSWICK (CANADA)
Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making hair thicker and darker. The effectiveness of this revolutionary solution was proven in the first two phases of clinical trials, where participants all observed positive results that ranged from moderate to ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX22, humanised IgG1 monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2). First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with trastuzumab and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It is the first China-developed adalimumab biosimilar that is manufactured in a China and Europe GMP certificated manufacturing site, as well as the only adalimumab biosimilar evaluated in a Phase 3 clinical study among Chinese patients with plaque ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
It can be used in combination with trastuzumab and chemotherapy for adjuvant treatment and neoadjuvant treatment for patients with HER2-positive BC and HER2-positive mBC. The first subject has been dosed in multi-centre phase 3 clinical trial of HLX11 for the neoadjuvant therapy in patients with HER2-positive, HR-negative early or locally advanced breast ...